foxo4 dri senolytic peptide animal model 2024 inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis Frontiers | Senolytic Peptide FOXO4-DRI

Has been a principal investigator for industry-sponsored clinical trials run by Novo Nordisk, Sanofi, Bayer, Johnson-Cilag and AbbVie

Peptide Information BPC-157 Peptide Structure Source: PubChem Lyophilized Peptides These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage

For monotherapy details, see the tirzepatide protocol page

It is important to note that while preclinical studies suggest promising therapeutic potential, clinical trials in humans are limited

The predominant part of the data comes from animal models and early observations, often ambiguous